System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 40813770 DOI: 10.1038/s41541-025-01251-5

A self-amplifying mRNA vaccine expressing PRV gD induces robust immunity against virulent mutants.

NPJ Vaccines 10(1):193

Authors: Tong Ling, Zhang Xin, Li Huan-Huan, Zheng Ya-Ting, Liu Ya-Mei, Guo Rong-Li, Armando Mario Damiani, Chen Sai-Sai, Zhang Chuan-Jian, Duan Rui, Mao Shu-Yu, Yu Jia-Li, Zhang Qian-Qian, Tao Ruo-Nan, Nikolaus Osterrieder, Xia Shu-Hua, Wang Ji-Chun

Affiliations

  • Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China.
  • National Research Center of Engineering and Technology for Veterinary Biology, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China.
  • Jiangsu Coinnovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, 225009, China.
  • GuoTai (Taizhou) Center of Technology Innovation for Veterinary Biology, Taizhou, 225300, China.
  • Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China. College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.
  • Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China. College of Animal Science and Technology, Guangxi University, Nanning, 530004, China.
  • Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China. National Research Center of Engineering and Technology for Veterinary Biology, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China. Jiangsu Coinnovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, 225009, China. GuoTai (Taizhou) Center of Technology Innovation for Veterinary Biology, Taizhou, 225300, China.
  • Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing, 210014, China.
  • Faculty of Medical Sciences, National University of Cuyo, Mendoza, 5500, Argentina.
  • Jinfa Pharmaceutical (Nanjing) Co, Ltd, Nanjing, 210032, China.
  • Tierärztliche Hochschule Hannover, Bünteweg 2, 30559, Hannover, Germany.
  • Jinfa Pharmaceutical (Nanjing) Co, Ltd, Nanjing, 210032, China.
  • Institute of Veterinary Immunology & Engineering, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China. National Research Center of Engineering and Technology for Veterinary Biology, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China. Jiangsu Coinnovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, 225009, China. GuoTai (Taizhou) Center of Technology Innovation for Veterinary Biology, Taizhou, 225300, China.

Abstract

Pseudorabies virus (PRV) causes an acute febrile infectious disease of pigs. Since 2011, PRV variants have appeared and spread nationwide in China. mRNA vaccines present a safe alternative and can stimulate humoral and cellular immunity. We constructed a self-amplifying mRNA (saRNA) vaccine containing gD gene of a highly virulent PRV variant. In mice, the PRV saRNA gD vaccine induced high levels of neutralizing antibodies. In piglets, vaccination with the PRV saRNA gD vaccine at a dose of as little as 5 μg induced very strong humoral immunity and cellular immunity, providing full protection against challenge infection with very virulent PRV variants. Protection following vaccination with saRNA gD induced significantly stronger protection than attenuated live vaccines and inactivated vaccines. In addition, our results confirm that a PRV saRNA vaccine expressing only one antigen can induce excellent protection in weaned piglets. Hence, the PRV saRNA gD vaccine might be a very promising substitute for inactivated and live vaccines. Finally, we provide proof-of-concept for the development of self-amplifying mRNA vaccines for members of the Alphaherpesvirinae, including herpes simplex virus 1 and 2 as well as varicella zoster virus.

MeSH

Vaccines, Rna, Messenger, Immunity, Cellular, Vaccination, Viruses, Immunity